Published in Gastroenterology on July 01, 2004
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol (2007) 1.70
Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology (2015) 1.65
Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology (2015) 1.65
Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations. Virchows Arch (2012) 1.63
Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat. Am J Physiol Gastrointest Liver Physiol (2012) 1.59
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Primary biliary cirrhosis. Semin Immunopathol (2009) 1.46
Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene (2009) 1.43
Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch (2006) 1.43
Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One (2011) 1.37
Bile formation and secretion. Compr Physiol (2013) 1.32
Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol (2006) 1.30
Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair (2013) 1.27
The genetics of complex cholestatic disorders. Gastroenterology (2013) 1.24
Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol (2009) 1.23
NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS One (2012) 1.17
The immunobiology of primary sclerosing cholangitis. Semin Immunopathol (2009) 1.15
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr (2008) 1.13
Biliary cholesterol secretion: more than a simple ABC. World J Gastroenterol (2010) 1.12
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (2011) 1.11
Cholangiocyte anion exchange and biliary bicarbonate excretion. World J Gastroenterol (2006) 1.08
Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol (2009) 1.07
Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol (2011) 1.04
Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography. Lab Invest (2013) 1.03
Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol (2012) 1.00
Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res (2014) 0.99
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol (2008) 0.96
Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am J Physiol Gastrointest Liver Physiol (2008) 0.95
Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease. World J Gastroenterol (2006) 0.94
Update on Sclerosing Cholangitis in Critically Ill Patients. Viszeralmedizin (2015) 0.93
Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol (2014) 0.89
Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology (2015) 0.88
Molecular mechanisms of cholestasis. Wien Med Wochenschr (2006) 0.88
Fibrosis in autoimmune and cholestatic liver disease. Best Pract Res Clin Gastroenterol (2011) 0.87
Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets. World J Gastroenterol (2006) 0.85
Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4-deficient mice. Am J Physiol Gastrointest Liver Physiol (2014) 0.85
Strong activation of bile acid-sensitive ion channel (BASIC) by ursodeoxycholic acid. Channels (Austin) (2012) 0.85
Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice. PLoS One (2010) 0.84
Epidermal growth factor protects the apical junctional complexes from hydrogen peroxide in bile duct epithelium. Lab Invest (2011) 0.84
Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis. Lab Invest (2014) 0.84
Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma. HPB (Oxford) (2011) 0.83
Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol (2014) 0.81
Vitamin D nuclear receptor deficiency promotes cholestatic liver injury by disruption of biliary epithelial cell junctions in mice. Hepatology (2013) 0.81
Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis. Oncotarget (2015) 0.80
Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res (2015) 0.79
Functional and structural features of cholangiocytes in health and disease. Cell Mol Gastroenterol Hepatol (2015) 0.79
All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice. J Pharmacol Exp Ther (2014) 0.79
ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression. J Gastroenterol (2015) 0.78
Experimental models of liver fibrosis. Arch Toxicol (2015) 0.78
Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC). Int J Mol Sci (2016) 0.77
CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol (2012) 0.77
Modeling hepatic osteodystrophy in Abcb4 deficient mice. Bone (2013) 0.77
Podoplanin discriminates distinct stromal cell populations and a novel progenitor subset in the liver. Am J Physiol Gastrointest Liver Physiol (2015) 0.77
Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis. J Biochem Mol Toxicol (2016) 0.77
Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies. Curr Pathobiol Rep (2014) 0.76
The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation. J Hepatol (2016) 0.76
Vitamin D modulates biliary fibrosis in ABCB4-deficient mice. Hepatol Int (2014) 0.76
Primary sclerosing cholangitis--the arteriosclerosis of the bile duct? Lipids Health Dis (2007) 0.76
Individuals with Primary Sclerosing Cholangitis Have Elevated Levels of Biomarkers for Apoptosis but Not Necrosis. Dig Dis Sci (2015) 0.76
Biliary phosphatidylcholine and lysophosphatidylcholine profiles in sclerosing cholangitis. World J Gastroenterol (2013) 0.75
Hepatobiliary anomalies associated with ABCB4/MDR3 deficiency in adults: a pictorial essay. Insights Imaging (2013) 0.75
Growth Hormone Mediates Its Protective Effect in Hepatic Apoptosis through Hnf6. PLoS One (2016) 0.75
Effects of Liver Fibrosis Progression on Tissue Relaxation Times in Different Mouse Models Assessed by Ultrahigh Field Magnetic Resonance Imaging. Biomed Res Int (2017) 0.75
The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation (2016) 0.75
Partial Portal Vein Arterialization Attenuates Acute Bile Duct Injury Induced by Hepatic Dearterialization in a Rat Model. Biomed Res Int (2016) 0.75
Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis. Toxicology (2016) 0.75
Hepatic cytochrome P450 deficiency in mouse models for intrahepatic cholestasis predispose to bile salt-induced cholestasis. Lab Invest (2014) 0.75
Generation of a cholangiocyte-specific cDNA expression library for the identification of B and T cell autoantigens in murine biliary disease. Hepatol Res (2012) 0.75
Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. World J Hepatol (2016) 0.75
Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study. Sci Rep (2016) 0.75
TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver. PLoS One (2016) 0.75
Mutations in TJP2, encoding zona occludens 2, and liver disease. Tissue Barriers (2015) 0.75
Epidermal growth factor signaling protects from cholestatic liver injury and fibrosis. J Mol Med (Berl) (2016) 0.75
Hepatitis B virus surface proteins accelerate cholestatic injury and tumor progression in Abcb4-knockout mice. Oncotarget (2017) 0.75
ABCB4 missense mutations D243A, K435T, G535D, I490T, R545C, and S978P significantly impair the lipid floppase and likely predispose to secondary pathologies in the human population. Cell Mol Life Sci (2017) 0.75
Cathepsin L and B as Potential Markers for Liver Fibrosis: Insights From Patients and Experimental Models. Clin Transl Gastroenterol (2017) 0.75
Embryonic cholecystitis and defective gallbladder contraction in the Sox17-haploinsufficient model of biliary atresia. Development (2017) 0.75
Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model. Dig Dis Sci (2012) 0.75
Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. Am J Pathol (2017) 0.75
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 5.33
Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab (2013) 4.88
Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology (2006) 4.70
Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA (2011) 4.21
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet (2003) 3.96
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96
p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol (2002) 3.80
Adipose triglyceride lipase contributes to cancer-associated cachexia. Science (2011) 3.70
Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology (2004) 3.66
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun (2004) 3.21
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep (2009) 3.03
Sedation in screening colonoscopy: impact on quality indicators and complications. Am J Gastroenterol (2012) 2.97
Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest (2011) 2.93
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol (2008) 2.85
Biobanking for Europe. Brief Bioinform (2007) 2.76
A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet (2007) 2.75
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol (2007) 2.72
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int (2009) 2.72
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology (2011) 2.67
Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol (2005) 2.66
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology (2005) 2.45
von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology (2012) 2.36
Loss of Lsc/p115 protein leads to neuronal hypoplasia in the esophagus and an achalasia-like phenotype in mice. Gastroenterology (2010) 2.35
Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med (2006) 2.33
Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr (2002) 2.32
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26
Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity (2011) 2.20
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (2005) 2.18
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest (2006) 2.16
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One (2010) 2.10
Paneth cells as a site of origin for intestinal inflammation. Nature (2013) 2.09
Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J (2006) 2.06
Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One (2009) 2.04
Neurocysticercosis in a European traveler returning from India primarily suspected as neoplasia. J Travel Med (2013) 1.96
Standardization of diagnostic PCR for the detection of foodborne pathogens. Int J Food Microbiol (2003) 1.95
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant (2011) 1.90
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87
The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol (2011) 1.87
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology (2005) 1.84
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut (2012) 1.83
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol (2005) 1.83
Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology (2008) 1.82
Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol (2012) 1.81
Agenesis of the dorsal pancreas and associated diseases. Dig Dis Sci (2008) 1.81
Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer (2003) 1.80
Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis (2010) 1.79
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79